Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
Prospective Evaluation of Patient Preferences for Outcomes of Hormonal Agents and Chemotherapy in Combination With Androgen Deprivation Therapy
1 other identifier
observational
1,020
1 country
1
Brief Summary
The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 3, 2021
CompletedFirst Submitted
Initial submission to the registry
May 11, 2022
CompletedFirst Posted
Study publicly available on registry
May 19, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 11, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 11, 2022
CompletedNovember 21, 2024
November 1, 2024
1.3 years
May 11, 2022
November 19, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Log-odds (preference weights) by participant cancer type and country
Log-odds indicate participants' relative preferences for treatments with each attribute level in the study, all else equal.
1 day (once through survey)
Secondary Outcomes (1)
Relative importance weights by participant type and country
1 day (once through survey)
Eligibility Criteria
Participants with mHSPC or locally-advanced prostate cancer with or without previous experience with ADT.
You may qualify if:
- For interviews (attribute prioritization and pretest interviews)
- Diagnosis of mHSPC with or without previous experience with ADT
- Able to read and understand the survey language
- Able to provide informed consent For online survey
- Diagnosis of mHSPC or locally-advanced prostate cancer with or without previous experience with ADT
- Able to read and understand the survey language
- Able to provide informed consent
You may not qualify if:
- Not applicable
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Duke Clinical Research Institute
Durham, North Carolina, 27701, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Astellas Pharma Global Development, Inc.
Astellas Pharma Global Development, Inc.
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 11, 2022
First Posted
May 19, 2022
Study Start
September 3, 2021
Primary Completion
December 11, 2022
Study Completion
December 11, 2022
Last Updated
November 21, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.